See more news releases in: Banking & Financial Services, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Clinical Trials & Medical Discoveries
Edison Pharmaceuticals, Inc. Closes Financing
Capital Directed to EPI-A0001 and EPI-743 Approval Trials
MOUNTAIN VIEW, Calif., Sept. 13, 2011 /PRNewswire/ -- Edison Pharmaceuticals, Inc. announced today that it has closed a Series E Preferred Financing. Capital raised will fund US and European approval trials for the company's clinical candidates, EPI-A0001 and EPI-743. Terms of the financing were not disclosed.
Edison Pharmaceuticals
Edison Pharmaceuticals is a patient- and physician-founded company devoted to developing new medicines to transform the lives of children and adults diagnosed with rare and neglected diseases. Currently, the company is focused on inherited mitochondrial diseases for which there are no approved drugs. These conditions are life-threatening and highly debilitating. Edison's specialized skill set spans the discovery, development, and translation of redox-based drugs.
edisonpharma.com
SOURCE Edison Pharmaceuticals, Inc.
Back to top
RELATED LINKS
http://www.edisonpharma.com
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
PR Newswire Membership
Fill out a PR Newswire membership form or contact us at (888) 776-0942.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.
Featured Video
More in These Categories
Journalists and Bloggers
![]()
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Free Investing Newsletter from Investor Uprising!
Learn to navigate the world's financial system and profit from leading companies.
Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All That Glitters: The Ultimate Gold Report".
- Site Preview
-
Close Site Preview
-
View FullScreen

